Cardiovascular disease: risk assessment and reduction, including lipid modification

well enough. For full details, see the guidance on bempedoic acid with ezetimibe (TA694, 2021). Secondary prevention of cardiovascular disease 1.10.3 Offer ezetimibe instead of a statin to people for whom statins are contraindicated or, if after documented discussion of the strategies outlined in recommendations 1.9.2 and 1.9.3, it is recognised the person cannot tolerate statins of any intensity or dose. This applies whatever the person's cholesterol level. Ezetimibe is recommended as an option in NICE technology appraisal guidance for treating primary hypercholesterolaemia in adults if statins are contraindicated or not tolerated. For full details, see the guidance on ezetimibe (TA385, 2016). [December 2023] 1.10.4 If the person is taking ezetimibe but the lipid target for secondary prevention is not met (see recommendation 1.7.1), consider alternative or additional lipid- lowering treatments recommended as options in NICE's technology appraisal guidance on: • alirocumab (TA393, June 2016) • bempedoic acid with ezetimibe (TA694, April 2021) • evolocumab (TA394, June 2016) • inclisiran (TA733, October 2021). See the relevant NICE technology appraisal guidance for full details. [December 2023] For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on lipid
